ANDA 91293, held by Sandoz. Idarubicin Hydrochloride.
As of Nov 22, 2026, ANDA 91293 (Idarubicin Hydrochloride), held by Sandoz, was first approved by FDA on Mar 29, 2011, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 29, 2011 | Original application | Approved | None posted |
| Idarubicin Hydrochloride5MG/5ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride10MG/10ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
| Idarubicin Hydrochloride20MG/20ML (1MG/ML) · solution;intravenous | Idarubicin Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters